IPO registrations (S-1, F-1) · Registrants
Traws Pharma, Inc.
- SEC CIK
- 1130598 · filings on EDGAR ↗
- Former names
- Onconova Therapeutics, Inc. (2010–2024); ONCONOVA THERAPEUTICS INC (2003–2009)
- Registration
- Form S-1, first filed 2013-06-14, last 2026-10-26; 7 initial registrations, 15 amendments
- Outcome
- Final prospectus filed 2013-07-25; declared effective 2013-07-24
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 12 PENNS TRAIL, Newtown, PA 18940
- Ticker
- TRAW (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Traws Pharma, Inc. on the corporate pages
On this site
- Business registration: Traws Pharma, Inc. Fuzzy (name and state)
- Form D issuer: Traws Pharma, Inc. EXACT (CIK (EXACT))
- SEC filer: Onconova Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 45
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-06-14 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001047469-13-006984 ↗ |
| 2013-07-11 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-13-007502 ↗ |
| 2013-07-18 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-13-007620 ↗ |
| 2013-07-23 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-13-007710 ↗ |
| 2013-07-24 | S-1MEF | S-1MEF (added securities) | Onconova Therapeutics, Inc. | 0001104659-13-056367 ↗ |
| 2013-07-24 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-13-002183 ↗ |
| 2013-07-25 | 424B4 | 424B4 (final prospectus) | Onconova Therapeutics, Inc. | 0001047469-13-007768 ↗ |
| 2014-11-20 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-14-003479 ↗ |
| 2015-10-20 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001104659-15-071664 ↗ |
| 2015-11-03 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-15-002954 ↗ |
| 2016-04-28 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-16-004363 ↗ |
| 2016-06-01 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001047469-16-013564 ↗ |
| 2016-06-20 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-16-013889 ↗ |
| 2016-06-29 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-16-014078 ↗ |
| 2016-07-01 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001047469-16-014131 ↗ |
| 2016-07-07 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-16-005100 ↗ |
| 2016-07-08 | 424B4 | 424B4 (final prospectus) | Onconova Therapeutics, Inc. | 0001047469-16-014224 ↗ |
| 2017-12-28 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-17-003344 ↗ |
| 2017-12-29 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001104659-17-075718 ↗ |
| 2018-01-30 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-004884 ↗ |
| 2018-02-06 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-006630 ↗ |
| 2018-02-07 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-006889 ↗ |
| 2018-02-07 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-18-000354 ↗ |
| 2018-02-09 | 424B4 | 424B4 (final prospectus) | Onconova Therapeutics, Inc. | 0001104659-18-008090 ↗ |
| 2018-04-17 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001104659-18-024558 ↗ |
| 2018-04-25 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-026322 ↗ |
| 2018-04-25 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-026660 ↗ |
| 2018-04-26 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-18-027164 ↗ |
| 2018-04-26 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-18-000940 ↗ |
| 2018-04-30 | 424B4 | 424B4 (final prospectus) | Onconova Therapeutics, Inc. | 0001104659-18-028129 ↗ |
| 2019-05-21 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-19-001161 ↗ |
| 2019-10-29 | S-1 | S-1 (registration) | Onconova Therapeutics, Inc. | 0001104659-19-057049 ↗ |
| 2019-11-12 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-19-062752 ↗ |
| 2019-11-14 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-19-063513 ↗ |
| 2019-11-21 | S-1/A | S-1/A (amendment) | Onconova Therapeutics, Inc. | 0001104659-19-066050 ↗ |
| 2019-11-21 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-19-002636 ↗ |
| 2019-11-25 | 424B4 | 424B4 (final prospectus) | Onconova Therapeutics, Inc. | 0001104659-19-066848 ↗ |
| 2020-05-18 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-20-001187 ↗ |
| 2023-07-11 | EFFECT | EFFECT (declared effective) | Onconova Therapeutics, Inc. | 9999999995-23-002065 ↗ |
| 2024-08-28 | EFFECT | EFFECT (declared effective) | Traws Pharma, Inc. | 9999999995-24-002661 ↗ |
| 2024-12-31 | 424B4 | 424B4 (final prospectus) | Traws Pharma, Inc. | 0001104659-24-132924 ↗ |
| 2025-01-22 | EFFECT | EFFECT (declared effective) | Traws Pharma, Inc. | 9999999995-25-000162 ↗ |
| 2026-05-15 | EFFECT | EFFECT (declared effective) | Traws Pharma, Inc. | 9999999995-26-001674 ↗ |
| 2026-07-09 | EFFECT | EFFECT (declared effective) | Traws Pharma, Inc. | 9999999995-26-002245 ↗ |
| 2026-10-26 | S-1 | S-1 (registration) | Traws Pharma, Inc. | 0001104659-26-118813 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Altland James | Officer | SVP, Finance & Corp. Develop. | 5 | 2013 | |
| BANSAL AJAY | Officer | Chief Financial Officer | 8 | 2013–2016 | |
| Baxter Healthcare SA | TenPercentOwner | 3 | 2013–2015 | ||
| BAXTER INTERNATIONAL INC | TenPercentOwner | 2 | 2013 | ||
| Bienen Henry S | Director | 11 | 2013–2018 | ||
| GROOPMAN JEROME | Director | 15 | 2013–2023 | ||
| Hoffman Michael B | Director; Director,TenPercentOwner | 20 | 2013–2020 | ||
| Kumar Ramesh | Director,Officer | Chief Executive Officer; President and CEO | 19 | 2013–2018 | |
| MCKEARN THOMAS J | Officer | President, R&D | 8 | 2013–2016 | |
| MEHTA VIREN | Director | 14 | 2013–2023 | ||
| Michael & Jane Hoffman 2013 Descendants | TenPercentOwner | 7 | 2013–2014 | ||
| Reddy E Premkumar | Director | 19 | 2013–2020 | ||
| VANLENT ANNE | Director | 4 | 2013–2015 | ||
| Guerin Mark Patrick | Officer | CFO; CFO AND COO; Chief Accounting Officer; Chief Financial Officer; COO and CFO | 31 | 2014–2025 | |
| Fruchtman Steven M | Director,Officer; Officer | Chief Medical Officer; President, Chief Executive Off; PRESIDENT, CHIEF EXECUTIVE OFF; President, Chief Medical Off | 27 | 2015–2024 | |
| Baxalta GmbH | TenPercentOwner | 1 | 2015 | ||
| Baxalta Inc | TenPercentOwner | 1 | 2015 | ||
| Maniar Manoj | Officer | SVP - Product Development | 12 | 2015–2020 | |
| MARINO JAMES J | Director | 19 | 2015–2023 | ||
| STOVER JACK E | Director | 16 | 2016–2026 | ||
| TYNDALL CAPITAL PARTNERS L P | TenPercentOwner | 13 | 2016–2019 | ||
| 683 Capital Management, LLC | Other; TenPercentOwner | 6 | 2018–2019 | ||
| 683 Capital Partners, LP | TenPercentOwner | 4 | 2018–2019 | ||
| Zweiman Ari | TenPercentOwner | 2 | 2018–2019 | ||
| Woodman Richard Charles | Officer | Chief Medical Officer | 4 | 2018–2020 | |
| OLER ABRAHAM N. | Officer | SVP Corp Dev & Gen Counsel; SVP CORP DEV & GEN COUNSEL; VP Corp Dev & Gen Counsel | 18 | 2018–2022 | |
| ARMISTICE CAPITAL, LLC | TenPercentOwner | 2 | 2019 | ||
| Armistice Capital Master Fund Ltd. | TenPercentOwner | 2 | 2019 | ||
| Boyd Steven | TenPercentOwner | 2 | 2019 | ||
| Shoemaker Mary Teresa | Director | 12 | 2020–2026 | ||
| Gelder Mark S. MD | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 8 | 2021–2023 | |
| Atadja Peter | Director | 3 | 2022–2023 | ||
| Clarke Trafford | Director | 8 | 2022–2026 | ||
| Moyo Victor M | Officer | CHIEF MEDICAL OFFICER | 2 | 2023 | |
| CAUTREELS WERNER | Director; Director,Officer | Chief Executive Officer | 9 | 2024–2026 | |
| Dukes Iain D. | Director,Officer | Chief Executive Officer; Executive Chairman | 7 | 2024–2026 | |
| ORBIMED ADVISORS LLC | Other; TenPercentOwner | 5 | 2024–2026 | ||
| OrbiMed Capital GP VIII LLC | Other; TenPercentOwner | 5 | 2024–2026 | ||
| Pauza Charles David | Officer | Chief Science Officer Virology | 6 | 2024–2026 | |
| Redfield Robert | Officer | Acting Chief Medical Officer; Chief Medical Officer | 6 | 2024–2026 | |
| Savchuk Nikolay | Director,Officer; Director,Officer,TenPercentOwner; Officer,TenPercentOwner | Chief Operating Officer | 9 | 2024–2026 | |
| TPAV, LLC | TenPercentOwner | 4 | 2024–2025 | ||
| Viriom, Inc. | TenPercentOwner | 1 | 2024 | ||
| Greenwood Luba | Director | 2 | 2024 | ||
| Brennan Nora | Officer | Interim CFO | 1 | 2025 | |
| Leaman John Harold | Director | 6 | 2025–2026 | ||
| Parker Charles Nolan | Officer | Chief Financial Officer | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-04-16 | Traws Pharma, Inc. | Biotechnology | $14,000,000 | $14,000,000 | 2 | 1 |
| 2019-06-04 | Onconova Therapeutics, Inc. | Biotechnology | $2,000,000 | $500,000 | 1 | 1 |
| 2018-06-08 | Onconova Therapeutics, Inc. | Biotechnology | $1,250,000 | $1,250,000 | 1 | 1 |
| 2015-10-23 | Onconova Therapeutics, Inc. | Biotechnology | $16,500,000 | $1,500,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.